Circle Pharma

Executive Summary

Circle Pharma is a privately held biotechnology company based in South San Francisco, California, pioneering macrocycle-based therapeutics for cancer treatment. The company’s proprietary MXMO platform enables the design of macrocycles that can target intracellular protein-protein interactions, which are typically considered 'undruggable' by conventional small molecules. By addressing these challenging targets, Circle aims to develop therapies with improved efficacy and reduced side effects compared to existing treatments. Founded in 2014, the company operates in the RNA & Gene Therapy category but focuses on macrocyclic peptides, a modality that combines the specificity of biologics with the oral bioavailability of small molecules. Circle Pharma is in the preclinical to early clinical stage, with no publicly disclosed pipeline or funding details. The company’s potential hinges on advancing its lead macrocycle candidates toward clinical trials and demonstrating target engagement and safety. Success could unlock novel cancer pathways and validate the MXMO platform for broader therapeutic applications. Given the high unmet need in oncology and the platform’s differentiation, Circle Pharma represents a high-risk, high-reward opportunity. Its near-term value drivers include clinical trial initiation, preclinical data presentations, and potential partnerships with larger biopharma firms seeking unique modalities.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 1 Clinical Trial for Lead Candidate30% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference (e.g., AACR or ASCO)70% success
• Q4 2026Strategic Partnership or Licensing Agreement for MXMO Platform40% success